109 related articles for article (PubMed ID: 25435253)
1. Modified 2,4-diaminopyrimidine-based dihydrofolate reductase inhibitors as potential drug scaffolds against Bacillus anthracis.
Nammalwar B; Bourne CR; Wakeham N; Bourne PC; Barrow EW; Muddala NP; Bunce RA; Berlin KD; Barrow WW
Bioorg Med Chem; 2015 Jan; 23(1):203-11. PubMed ID: 25435253
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of Bacillus cereus and Bacillus anthracis dihydrofolate reductase: toward the identification of new potent drug leads.
Joska TM; Anderson AC
Antimicrob Agents Chemother; 2006 Oct; 50(10):3435-43. PubMed ID: 17005826
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of bacterial dihydrofolate reductase by 6-alkyl-2,4-diaminopyrimidines.
Nammalwar B; Bourne CR; Bunce RA; Wakeham N; Bourne PC; Ramnarayan K; Mylvaganam S; Berlin KD; Barrow EW; Barrow WW
ChemMedChem; 2012 Nov; 7(11):1974-82. PubMed ID: 22930550
[TBL] [Abstract][Full Text] [Related]
4. In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.
Barrow EW; Dreier J; Reinelt S; Bourne PC; Barrow WW
Antimicrob Agents Chemother; 2007 Dec; 51(12):4447-52. PubMed ID: 17875993
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological activity of substituted 2,4-diaminopyrimidines that inhibit Bacillus anthracis.
Nammalwar B; Bunce RA; Berlin KD; Bourne CR; Bourne PC; Barrow EW; Barrow WW
Eur J Med Chem; 2012 Aug; 54():387-96. PubMed ID: 22703705
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship for enantiomers of potent inhibitors of B. anthracis dihydrofolate reductase.
Bourne CR; Wakeham N; Nammalwar B; Tseitin V; Bourne PC; Barrow EW; Mylvaganam S; Ramnarayan K; Bunce RA; Berlin KD; Barrow WW
Biochim Biophys Acta; 2013 Jan; 1834(1):46-52. PubMed ID: 22999981
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 2,4-diaminopyrimidine-based antifolate drugs against Bacillus anthracis.
Nammalwar B; Muddala NP; Bourne CR; Henry M; Bourne PC; Bunce RA; Barrow EW; Berlin KD; Barrow WW
Molecules; 2014 Mar; 19(3):3231-46. PubMed ID: 24642909
[TBL] [Abstract][Full Text] [Related]
8. Targeted mutations of Bacillus anthracis dihydrofolate reductase condense complex structure−activity relationships.
Beierlein JM; Karri NG; Anderson AC
J Med Chem; 2010 Oct; 53(20):7327-36. PubMed ID: 20882962
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity.
Bourne CR; Bunce RA; Bourne PC; Berlin KD; Barrow EW; Barrow WW
Antimicrob Agents Chemother; 2009 Jul; 53(7):3065-73. PubMed ID: 19364848
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling toward selective inhibitors of dihydrofolate reductase from the biological warfare agent Bacillus anthracis.
Giacoppo JO; Mancini DT; Guimarães AP; Gonçalves AS; da Cunha EF; França TC; Ramalho TC
Eur J Med Chem; 2015 Feb; 91():63-71. PubMed ID: 24985033
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
Chan DC; Fu H; Forsch RA; Queener SF; Rosowsky A
J Med Chem; 2005 Jun; 48(13):4420-31. PubMed ID: 15974594
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity correlations for three pyrido[2,3-d]pyrimidine antifolates binding to human and Pneumocystis carinii dihydrofolate reductase.
Cody V; Pace J; Namjoshi OA; Gangjee A
Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):799-803. PubMed ID: 26057816
[TBL] [Abstract][Full Text] [Related]
13. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
Gangjee A; Guo X; Queener SF; Cody V; Galitsky N; Luft JR; Pangborn W
J Med Chem; 1998 Apr; 41(8):1263-71. PubMed ID: 9548816
[TBL] [Abstract][Full Text] [Related]
14. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
15. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
Peppard WJ; Schuenke CD
Curr Opin Investig Drugs; 2008 Feb; 9(2):210-25. PubMed ID: 18246524
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
[TBL] [Abstract][Full Text] [Related]
17. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
[TBL] [Abstract][Full Text] [Related]
18. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
Gangjee A; Adair O; Queener SF
J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
[TBL] [Abstract][Full Text] [Related]
19. Analysis of quinazoline and pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase.
Cody V; Galitsky N; Luft JR; Pangborn W; Queener SF; Gangjee A
Acta Crystallogr D Biol Crystallogr; 2002 Sep; 58(Pt 9):1393-9. PubMed ID: 12198294
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Gangjee A; Adair OO; Queener SF
J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
